LUNGevity's London Gambit: A Global Stage for a Silent Killer

BETHESDA, Md. – July 30, 2026 – In the competitive world of nonprofit fundraising, securing a high-profile platform can be the difference between incremental gains and transformative impact. The LUNGevity Foundation has just executed a masterstroke, securing a coveted spot as one of only two U.S. lung cancer charities in the 2027 Double TCS London Marathon. This isn't just another charity partnership; it's a strategic entry into what is being billed as the largest marathon and single-biggest fundraising event in UK sport history. By placing itself at the heart of this global spectacle, LUNGevity is making a calculated move to elevate its fight against the world's deadliest cancer from a national mission to a global crusade.

The 2027 event is a one-off behemoth. For the first time, the London Marathon will unfold over two days, sending an unprecedented 100,000 runners through the city's iconic streets. This expansion is designed with a singular purpose: to shatter fundraising records, with organizers projecting a haul of over £150 million for good causes. For LUNGevity, gaining access to this fundraising engine is a monumental win, providing a direct channel to a new, international pool of athletes and donors.

A Strategic Leap onto the World Stage

This partnership marks a significant milestone in LUNGevity's operational strategy. With the addition of London, the foundation's endurance program, Team LUNGevity, is now an official charity partner for seven of the eight Abbott World Marathon Majors. This near-complete presence on the world's most prestigious marathon circuit is a powerful statement of intent. It transforms the organization from a primarily U.S.-focused entity into a global player in the endurance fundraising space, a market where brand association and large-scale events are paramount.

The move is backed by a proven track record of fiscal responsibility and mission-focused spending. LUNGevity has consistently earned a 4-star rating from Charity Navigator, the highest possible score, signifying exceptional financial health and transparency. With an impressive 86% of its expenses channeled directly into its programs for research, patient support, and advocacy, the foundation demonstrates a lean and effective operational model. This credibility is crucial when asking runners to commit to significant fundraising goals in exchange for a guaranteed race entry. Donors and participants can be confident that their efforts will fuel tangible progress, not administrative overhead. Last fiscal year alone, Team LUNGevity athletes raised nearly $750,000, a figure poised for substantial growth with the addition of London's massive platform.

The Human Engine Powering the Mission

Behind the strategic calculus and financial projections lies the human engine that drives the mission: a passionate community of runners, many with a deeply personal connection to the cause. Team LUNGevity is comprised of survivors, caregivers, and individuals running in memory of loved ones, each turning their personal grief and hope into kinetic energy for change.

"Every runner who joins our team helps accelerate research, provide hope and support for patients and families, and raise awareness that anyone with lungs can get lung cancer," said Katie Ginda, Director of Development at LUNGevity Foundation. "We're especially inspired by the survivors who choose to run with us, proving every day what's possible because of continued advances in research."

These are not just token stories. They are powerful testaments to the impact of medical innovation. Survivors who, a decade ago, might have faced a grim prognosis are now training for and completing one of the world's most demanding endurance events. Their participation serves a dual purpose: it is a personal victory over a devastating disease and a public demonstration that a lung cancer diagnosis is not an automatic death sentence. This visibility is invaluable in shifting public perception and inspiring hope within the patient community. The foundation supports these athletes with personalized fundraising coaching, team apparel, and a built-in community, transforming a solitary training journey into a collective effort.

Beyond the Finish Line: Confronting a Public Health Crisis

The spectacle of the London Marathon provides a crucial platform to broadcast an urgent message. Lung cancer is a silent and misunderstood epidemic. It is the leading cause of cancer death in the United States, claiming more lives than colorectal, pancreatic, and breast cancers combined. A new diagnosis occurs every 2.3 minutes in the U.S., yet the disease fights a constant battle against stigma and misinformation.

A pervasive, and incorrect, public perception links the disease exclusively to smoking. However, the data tells a different story: an estimated 65% of all new lung cancer diagnoses are among people who have never smoked or are former smokers. This statistic underscores a critical point LUNGevity aims to amplify: if you have lungs, you can get lung cancer. This awareness is vital for driving policy change and encouraging screenings.

The survival statistics are equally stark. The overall five-year survival rate for lung cancer hovers at a grim 29.5%. Yet, there is a clear path to changing this outcome. If the cancer is detected at an early stage, before it has spread, that survival rate skyrockets to 65.5%. Despite this, screening rates remain dangerously low. In the U.S., only a small fraction of the eligible high-risk population undergoes recommended annual low-dose CT screening. LUNGevity's high-profile presence in London is a strategic tool to hammer home the life-saving importance of early detection and to advocate for policies that improve access to screening and care.

Paving the Way from Pavement to Progress

The funds raised by Team LUNGevity runners will not simply disappear into a general fund. They are targeted investments aimed at solving the most pressing challenges in lung cancer treatment and care. Having already directed over $55 million toward scientific advancement since its inception, LUNGevity is the largest nonprofit funder of lung cancer research in the U.S. Its strategy is multi-pronged: funding research into early detection, backing clinical trials to overcome treatment resistance, and investing in the next generation of oncology researchers.

This focus on the entire research pipeline—from discovery to clinical application—is what makes its fundraising so potent. Funds raised in London will help support initiatives like the foundation's partnership with the Rising Tide Foundation for Clinical Cancer Research, which offers up to $1 million per project for trials focused on drug resistance and early detection of recurrence. By transforming marathon miles into research dollars, LUNGevity is systematically building the infrastructure needed to achieve its ultimate vision: a world where no one dies of lung cancer.